Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
41.24
+0.07 (0.17%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Exelixis Revenue
In the year 2025, Exelixis had annual revenue of $2.32B with 6.98% growth. Exelixis had revenue of $598.66M in the quarter ending December 31, 2025, with 5.63% growth.
Revenue (ttm)
$2.32B
Revenue Growth
+6.98%
P/S Ratio
4.62
Revenue / Employee
$2,154,249
Employees
1,077
Market Cap
10.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.32B | 151.43M | 6.98% |
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| BioMarin Pharmaceutical | 3.22B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| Axsome Therapeutics | 638.50M |
| BridgeBio Pharma | 502.08M |
| ImmunityBio | 113.29M |
EXEL News
- 4 days ago - Exelixis, Inc. (EXEL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Exelixis, Inc. (EXEL) Presents at The Citizens Life Sciences Conference 2026 Transcript - Seeking Alpha
- 5 days ago - Exelixis, Inc. (EXEL) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 12 days ago - Exelixis, Inc. (EXEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 19 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March - Business Wire
- 4 weeks ago - Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 5 weeks ago - Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer - Business Wire